Literature DB >> 20053142

Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.

Wadchara Pumpradit1, Jintanat Ananworanich, Sermsak Lolak, Cecilia Shikuma, Robert Paul, Umaporn Siangphoe, Nithima Chaoniti, Peeraporn Kaew-On, Robert Paris, Kiat Ruxrungtham, Victor Valcour.   

Abstract

This research is a cross-sectional study to determine the frequency of neurocognitive impairment and psychiatric comorbidity among Thais maintained on highly active antiretroviral therapy (HAART) with undetectable plasma human immunodeficiency virus (HIV) RNA in the 2NN Cohort. Sixty-four subjects were evaluated with neurological examinations, neuropsychological testing, and psychiatric questionnaires. Twenty-four subjects (37.5%) were found to have neurocognitive impairment, with 13 (20.3%), 10 (15.6%), and 1 (1.6%) classified as asymptomatic neurocognitive disorder (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD), respectively. Three subjects (4.7%) had depression and no cases had significant symptoms of anxiety. A notable proportion of well-controlled individuals exhibited neurocognitive impairment. Anxiety and depression were uncommon.

Entities:  

Mesh:

Year:  2010        PMID: 20053142     DOI: 10.3109/13550280903493914

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  25 in total

Review 1.  HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity.

Authors:  Ned Sacktor; Noeline Nakasujja; Kevin Robertson; David B Clifford
Journal:  Nat Clin Pract Neurol       Date:  2007-08

2.  The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes.

Authors:  J R Brechtl; W Breitbart; M Galietta; S Krivo; B Rosenfeld
Journal:  J Pain Symptom Manage       Date:  2001-01       Impact factor: 3.612

3.  Nature of depression in patients with HIV/AIDS.

Authors:  Fiona Judd; Angela Komiti; Phyllis Chua; Anne Mijch; Jennifer Hoy; Paul Grech; Alan Street; John Lloyd; Ben Williams
Journal:  Aust N Z J Psychiatry       Date:  2005-09       Impact factor: 5.744

4.  Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.

Authors:  T Gibbie; A Mijch; S Ellen; J Hoy; C Hutchison; E Wright; P Chua; F Judd
Journal:  HIV Med       Date:  2006-03       Impact factor: 3.180

5.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

6.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

7.  Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.

Authors:  Adriana Ammassari; Andrea Antinori; Maria Stella Aloisi; Maria Paola Trotta; Rita Murri; Luca Bartoli; Antonella D'Arminio Monforte; Albert W Wu; Fabrizio Starace
Journal:  Psychosomatics       Date:  2004 Sep-Oct       Impact factor: 2.386

8.  The prevalence and incidence of neurocognitive impairment in the HAART era.

Authors:  Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

9.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

10.  Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.

Authors:  Anne C Roc; Beau M Ances; Sanjeev Chawla; Marc Korczykowski; Ronald L Wolf; Dennis L Kolson; John A Detre; Harish Poptani
Journal:  Arch Neurol       Date:  2007-07-09
View more
  22 in total

Review 1.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

Review 2.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

Review 3.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

4.  Prevalence and Risk Factors of HIV-Associated Neurocognitive Disorders in Rural Southwestern Uganda.

Authors:  Jane Kasozi Namagga; Godfrey Zari Rukundo; Joachim G Voss
Journal:  J Assoc Nurses AIDS Care       Date:  2019 Sep-Oct       Impact factor: 1.354

5.  Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.

Authors:  Torsak Bunupuradah; Ploenchan Chetchotisakd; Supunnee Jirajariyavej; Victor Valcour; Chureeratana Bowonwattanuwong; Warangkana Munsakul; Virat Klinbuayaem; Wisit Prasithsirikul; Jiratchaya Sophonphan; Apicha Mahanontharit; Bernard Hirschel; Sorakij Bhakeecheep; Kiat Ruxrungtham; Jintanat Ananworanich
Journal:  J Neurovirol       Date:  2012-09-20       Impact factor: 2.643

Review 6.  Neurology and the Global HIV Epidemic.

Authors:  Ana-Claire Meyer
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

7.  Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia.

Authors:  Trena Mukherjee; Rishanantini Sakthivel; Ho Yen Fong; Megan McStea; Meng Li Chong; Sharifah Faridah Omar; Ai Vyrn Chin; Shahrul Kamaruzzaman; Adeeba Kamarulzaman; Reena Rajasuriar; Lucette A Cysique
Journal:  AIDS Behav       Date:  2018-10

8.  Global NeuroAIDS roundtable.

Authors:  Jeymohan Joseph; Cristian L Achim; Michael J Boivin; Bruce J Brew; David B Clifford; Deborah A Colosi; Ronald J Ellis; Robert K Heaton; Amadou Gallo-Diop; Igor Grant; Georgette D Kanmogne; Mahendra Kumar; Scott Letendre; Thomas D Marcotte; Avindra Nath; Carlos A Pardo; Robert H Paul; Lynn Pulliam; Kevin Robertson; Walter Royal; Ned Sacktor; Pasiri Sithinamsuwan; Davey M Smith; Victor Valcour; Brian Wigdahl; Charles Wood
Journal:  J Neurovirol       Date:  2013-01-26       Impact factor: 2.643

Review 9.  Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model.

Authors:  Angela M Amedee; Whitney A Nichols; Spencer Robichaux; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

Review 10.  The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.

Authors:  Henry Ukachukwu Michael; Sasha Naidoo; Kofi Boamah Mensah; Suvira Ramlall; Frasia Oosthuizen
Journal:  AIDS Behav       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.